Abstract
Adjuvants have been used to augment the immune response to antigens in experimental immunology and vaccination purposes for 70 years (Ramon, 1925, 1926; Glenny et al., 1926). Traditionally, adjuvants have been used with routine human vaccines to elicit an early, high and long lasting immune response. But in recent years adjuvants received much attention because of: 1) poor immunogenicity of newly developed purified, subunit and synthetic vaccines which need adjuvants to evoke the immune response, and 2) selective modulation of immune response by adjuvants with regard to major histocompatibility complex (MHC) class (I or II) and T-helper cell type (Th1 or Th2) which is very important for protection against diseases caused by intracellular pathogens such as viruses, parasites and bacteria (Gupta and Siber, 1995a). Additionally, with the use of adjuvants, less antigen may be required to stimulate the immune response which would not only be a saving on cost of vaccines, it would be useful in the development of combination vaccines, thus reducing the complications due to antigen competition and carrier specific epitope suppression. In this paper, an overview on the role of adjuvants in modulation of immune response to vaccine antigens is presented.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Allison, A.C., and Byars, N.E., 1990, Adjuvants for a new generation of vaccines, in: New Generation Vaccines (G.C. Woodrow, and M.M. Levine, eds.), Marcel Dekker, New York, pp. 129–140.
Alonso, M.J., Gupta, R.K., Min, C., Siber, G.R., and Langer, R., 1994, Biodegradable microspheres as controlled-release tetanus toxoid delivery systems, Vaccine 12:299–306.
Aprile, M.A., and Wardlaw, A.C., 1966, Aluminum compounds as adjuvants for vaccine and toxoids in man: A review, Can. J. Publ. Health 57:343–354.
Audibert, F.M., and Lise, L.D., 1993, Adjuvants: current status, clinical perspectives and future prospects, Immunology Today 14:281–284.
Barington, T., Skettrup, M., Juul, L., and Heilman, C., 1993, Non-epitope-specific suppression of the antibody response to Haemophilus influenzae type b conjugate vaccines by preimmunization with vaccine components, Infect. Immun. 61:432–438.
Cooper, P.D., 1994, The selective induction of different immune responses by vaccine adjuvants, in: Strategies in Vaccine Design (G.L. Ada ed.), R.G. Landes Company, Austin, pp. 125–158.
Coutelier, J.P., van der Logt, J.T., Heessen, F.W.A., Warmer, G., and van Snick, J., 1987, IgG2a restriction of murine antibodies elicited by viral infections, J. Exp. Med. 165:64–69.
Dahlback, M., Bergstr, H., Pauwels, R., and Bazin, H., 1983, The non-specific enhancement of allergy III. Precipitation of bronchial anaphylactic reactivity in primed rats by injection of alum or B. pertussis vaccine: Relation of response capacity to IgE and IgG2a antibody levels, Allergy 38:261–271.
Eldridge, J.H., Gilley, R.M., Staats, J.K., Moldoveanu, Z., Meulbroek, J.A., and Tice, T.R., 1989, Biodegradable microspheres: vaccine delivery system for oral immunization, Curr. Topics Microbiol. Immunol. 146:59–66.
Eldridge, J.H., Staas, J.K., Meulbroek, J.A., Tice, T.R., and Gilley R.M., 1991, Biodegradable and biocompatible polyCDL-lactide-co-glycolide) microspheres as an adjuvant for Staphylococcal enterotoxin B toxoid which enhances the level of toxin-neutralizing antibodies, Infect. Immun. 59:2978–2986.
Ellis, R.W., and Douglas, R.G., Jr., 1994, Combination vaccines, Int. J. Technol. Assess. Hlth care 10:185–192.
Food and Drug Administration, 1993a, Approval of a new Haemophilus influenzae type b conjugate vaccine and a combined diphtheria-tetanus-pertussis and Haemophilus influenzae type b conjugate vaccine for infants and children, MMWR 42:296–298.
Food and Drug Administration, 1993b, Approval of use of Haemophilus influenzae type b conjugate vaccine reconstituted with diphtheria-tetanus-pertussis vaccine for infants and children. MMWR 42:964–966.
Glenny, A.T., Pope, C.G., Waddington, H., and Wallace, U., 1926, The antigenic value of toxoid precipitated by potassium alum, J. Pathol. Bacteriol. 29:38–45.
Golding, B., 1991, Cytokine regulation of humoral immune responses, in: Topics in Vaccine Adjuvant Research (D.R. Spriggs, and W.C. Koff, eds.), CRC, Boca Raton, pp. 25–37.
Gupta, R.K., and Siber, G.R., 1994a, Comparison of adjuvant activities of aluminum phosphate, calcium phosphate and stearyl tyrosine for tetanus toxoid, Biologicals 22:53–63.
Gupta, R.K., and Siber, G.R., 1994b, Comparative analysis of tetanus antitoxin titers of sera from immunized mice and guinea pigs determined by toxin neutralization test and enzyme-linked immunosorbent assay, Biologicals 22:215–219.
Gupta, R.K., and Siber, G.R., 1995a, Adjuvants for human use: current status, problems and future prospects, Vaccine 13:1263–1276.
Gupta, R.K., and Siber, G.R., 1995b, Method for quantitation of IgG subclass antibodies in mouse serum by enzyme-linked immunosorbent assay, J. Immunol. Methods 181:75–81.
Gupta, R.K., Relyveld, E.H., Lindblad, E.B., Bizzini, B., Ben-Efraim, S., and Gupta C.K., 1993a, Adjuvants-a balance between toxicity and adjuvanticity, Vaccine 11:293–306.
Gupta, R.K., Siber, G.R., Alonso, M.J., and Langer, R., 1993b, Development of a single-dose tetanus toxoid based on controlled release from biodegradable and biocompatible polyester microspheres, in: Vaccines 93 (F. Brown, R. Chanock, H. Ginsberg, and R. Lerner, eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp. 391–396.
Gupta, R.K., Higham, S., Gupta, C.K., Rost, B., and Siber, G.R., 1994a, Suitability of the Vero cell method for titration of diphtheria antitoxin in the United States potency test for diphtheria toxoid, Biologicals 22:65–72.
Gupta, R., Griffin, P., Lees, A., Mond, J., Varanelli, C., Wallach, D., Cooper, P., Alonso, M., Langer, R. and Siber, G., 1994b, Comparative evaluation of aluminum phosphate, calcium phosphate, stearyl tyrosine, γ inulin, conjugation to dextran, liposomes and poly lactide/glycolide microspheres as adjuvant delivery systems for tetanus and diphtheria toxoids. Paper presented at the 94th General Meeting of the American Society for Microbiology, May 23-27, 1994, at Las Vegas, NV. American Society for Microbiology, Washington, DC, p. 147.
Gupta, R.K., Siber, G.R., Lees, A. and Mond, J.J., 1994c, Conjugation of multiple copies of T-cell dependent antigens on a large molecular weight polysaccharide carrier enhances antibody response to both components. Paper presented at the Second International Conference on Vaccines: New Technologies & Applications, March 21–23, 1994, Alexandria, VA. Waltham: Cambridge Healthtech Institute.
Gupta, R.K., Rost, B.E., Relyveld, E., and Siber, G.R., 1995a, Adjuvant Properties of aluminum and calcium compounds, in: Vaccine Design: The Subunit Approach (M.F. Powell, and M.J. Newman, eds.), Plenum Publishing Corporation, New York, pp 229–248.
Gupta, R.K., Anderson, R., Cecchini, D., Rost, B., Griffin, P., Benscoter, K., Xu, J., Montanez-Ortiz, L., and Siber, G.R., 1995b, Development of a guinea-pig model for potency/immunogenicity evaluation of diphtheria, tetanus, acellular pertussis (DTaP) and Haemophilus influenzae type b polysaccharide conjugate vaccines, Dev. Biol. Stand, 86:281–294.
Gupta, R.K., Varanelli, C.L., Griffin, P., Wallach, D.F.H. and Siber, G.R., 1995c, Adjuvant properties of non-phospholipid liposomes (Novasomes®) in experimental animals for human vaccine antigens. Vaccine (in press).
Herzenberg, L.A., Tokuhisa, T. and Hayakawa, K, 1983, Epitope-specific regulations, Ann. Rev. Immunol. 1:609–632.
Kensil, C.R., Newman, M.J., Coughlin, R.T., Soltysik, S., Bedore, D., Recchia, J., Wu, J.-Y, and Marciani, DJ., 1993, The use of Stimulon adjuvant to boost vaccine response, Vacc. Res. 2:273–282.
Martin, S., Daniel, S.L., and Rouse, B.T., 1991, Cytokines and regulation of cellular immune responses to viruses, in: Topics in Vaccine Adjuvant Research (D.R. Spriggs, and W.C. Koff, eds.), CRC, Boca Raton, pp. 39–50.
Morris, W., Steinhoff, M.C., and Russell, P.K., 1994, Potential of polymer microencapsulation technology for vaccine innovation, Vaccine 12:5–11.
Neefjes, J.J., Schumacher. T.N.M., and Ploegh, H.L., 1991, Assembly and intracellular transport of major histocompatibility complex molecules. Curr. Opin. Cell. Biol. 3:601–609.
O’Hagan, D.T., Jeffery, H., and Davis, S.S., 1993, Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles, Vaccine 11:965–969.
Paul, WE., 1993, The immune system, in: Fundamental Immunology (W.E. Paul, ed.) Third Edition, Raven Press, New York, pp. 1–20.
Ramon, G., 1925, Sur l’augmentation anormale de l’antitoxine chez les chevaux producteurs de serum antidiphtérique, Bull. Soc. Centr. Med. Vet. 101:227–234.
Ramon, G., 1926, Procedres pour acroitre la production des antitoxines, Ann. Institut Pasteur 40:1–10.
Robbins, J.B., and Schneerson, R., 1990, Polysaccharide-protein conjugates: a new generation of vaccines. J. Infect. Dis. 161:821–832.
Salk, J., Bretscher, P.A., Salk, P.L., Clerici, M., and Shearer, G.M., 1993, A strategy for prophylactic vaccination against HIV, Science 260:1269–1271.
Shearer, G.M., and Clerici, M., 1994, CD4+ functional T cell subsets: their roles in infection and vaccine development, in: Strategies in Vaccine Design (G.L. Ada ed.), R.G. Landes Company, Austin, pp. 113–124.
Siber, G.R., 1994, Pneumococcal disease: Prospects for a new generation of vaccines, Science 265:1385–1387.
Singh, M., Singh, O., Singh, A., and Talwar, G.P., 1992, Immunogenicity studies on diphtheria toxoid loaded biodegradable microspheres, Int. J. Pharmaceutics 85:R5–R8.
Staats, H.F., Jackson, R.J., Marinaro, M., Takahashi, I., Kiyono, H., and McGhee, J.R., 1994, Mucosal immunity to infection with implications for vaccine development, Curr. Biol. 6:572–583.
Takahashi, H., Takeshita, T., Morein, B., Putney, S., Germain, R.N., and Berzofsky, J.A., 1990, Induction of CD8+ cytotoxic T-cells by immunization with purified HIV-1 envelope protein in ISCOMs, Nature (London) 344:873–875.
Wu, J.-Y., Gardner, B.H., Murphy, C.I., Seals, J.R., Kensil, C.R., Recchia, J., Beltz, G.A., Newman, G.W., and Newman, M.J., 1992, Saponin adjuvant enhancement of antigen specific immune responses to an experimental HIV-1 vaccine, J. Immunol. 148:1519–1525.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer Science+Business Media New York
About this chapter
Cite this chapter
Gupta, R.K. et al. (1996). The Role of Adjuvants and Delivery Systems in Modulation of Immune Response to Vaccines. In: Cohen, S., Shafferman, A. (eds) Novel Strategies in the Design and Production of Vaccines. Advances in Experimental Medicine and Biology, vol 397. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-1382-1_15
Download citation
DOI: https://doi.org/10.1007/978-1-4899-1382-1_15
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-1384-5
Online ISBN: 978-1-4899-1382-1
eBook Packages: Springer Book Archive